从2024半年报来看，海正药业实现总营收52.43亿元，同比减少13.48%，归母净利润4.35亿元，同比增加7.7%。具体到业务板块，海正药业内分泌药H1实现收入2.23亿元，同比增加67.67%。对此，肖卫红表示，主要是奥利司他、阿卡波糖等产品上半年销售同比有较大增长。During the earnings conference, Zhejiang Hisun Pharmaceutical's CFO explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution and raw material business.
In today's earnings conference, Zhejiang Hisun Pharmaceutical's CFO, Jiang Ling, explained to the Finance Associated Press that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution and raw material business. In addition, CEO Xiao Weihong answered questions about the growth of endocrine medicine revenue and the future business model of the animal health sector.
Regarding the decrease in H1 revenue, Jiang Ling responded to the Finance Associated Press that it was mainly due to the company's strategic abandonment of low-margin pharmaceutical distribution and raw material business, which accounted for more than 50% of the year-on-year total decrease, as well as the impact of not being selected for the eighth batch of group procurement products, including I VNest, despite many choices. At the same time, Xiao Weihong revealed that the overall capacity utilization rate of the company's raw material business is less than 50%.
According to the 2024 semi-annual report, Zhejiang Hisun Pharmaceutical achieved a total revenue of 5.243 billion yuan, a decrease of 13.48% compared to the same period last year, and a net income attributable to the parent company of 0.435 billion yuan, an increase of 7.7% compared to the same period last year. Specifically, Zhejiang Hisun Pharmaceutical's endocrine medicine business achieved revenue of 0.223 billion yuan in H1, a year-on-year increase of 67.67%. In response, Xiao Weihong stated that this was mainly due to a significant increase in sales of products such as Olisat and Acarbose in the first half of the year.
In the animal health sector, Zhejiang Hisun Pharmaceutical stated in the semi-annual report that the business was under significant pressure due to factors such as widespread losses in downstream economic animal farming, sluggish consumer demand in the pet industry, and increasing competition.
During the earnings conference, Xiao Weihong further explained that the overall loss of YUNSHENG Company directly led to a loss at the overall level of the animal health sector. At the same time, he stated that the company will gradually adjust the business model of economic animal operations, increase the contribution of the pet business to revenue, and enhance the contribution of animal health to the listed company.
Zhejiang Hisun Pharmaceutical's animal health business includes four sectors: pig farming, pet business, ruminant business, and vaccine business. The company's secretary, Shen Xifei, told the Finance Associated Press that the company currently has four pig vaccines and three pet biological preparations under development, with research and development tasks undertaken by Hisun Animal Health and production implemented by YUNSHENG Company.